Healthcare


Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities
Share this:
Published: 4 Sep 2018

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally enabled by the entry of non-traditional tech companies such as Apple, Facebook, and Google—pushing pharmaceutical companies to go beyond-the-pill. However, in the midst of this chaos, there are pioneering companies offering solutions that apply cutting-edge digital technologies such as AI, Big Data and analytics, cloud, mobile, blockchain, and Internet of Things (IoT) to build digital convergence across the pharmaceutical value chain, covering R&D, manufacturing and operations, marketing, and patient connect. This Companies to Action (C2A) analysis puts the spotlight on such game-changing, tech-enabled participants and how they are altering the status-quo by highlighting novel monetization models and strategic investment opportunities.

  1.  
  2.  
  3.  
  4.  
  5.  
  6.  
  7.  

Tools

Features of this research

SUBSCRIPTIONS

Help Desk

Full list of offices


For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..